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ABSTRACT 
Background: Preterm delivery affects six to twelve per cent of all pregnant women each 
year. Treatment with antenatal corticosteroids (ACS) has contributed greatly to improve 
outcome after preterm birth. It is administered to women at risk for preterm delivery to 
reduce the risk of respiratory distress syndrome (RDS) and death of her preterm infant. The 
protective effect of ACS declines after 7-10 days. Considering that up to 50% of women 
remain undelivered 7-10 days after ACS administration, and in view of the neonatal benefits, 
repeat courses of ACS could be considered. However, unresolved concerns about safety still 
make such treatment regime controversial. Furthermore, it is not clear whether ACS is 
effective also in extremely preterm gestations. 
Objective: The overall objective with this thesis was to investigate the impact of repeat 
courses of ACS in exposed subjects, both on infant size at birth, and on longer term outcomes 
(study I-III). Another objective was to explore the association between timing of ACS 
administration and survival in extremely preterm infants (study IV). 
Methods: All studies in the thesis are cohort studies. In study I-III we used a cohort of about 
100 children exposed to various courses of ACS in utero. We evaluated them regarding infant 
anthropometry at birth (study I), and risk factors for cardiovascular disease (study II) and 
neuropsychological function (study III) at follow up in adolescence/young adulthood. In 
study IV we evaluated a national population-based cohort of extremely preterm infants 
(EXPRESS – Extremely Preterm Infant in Sweden Study) regarding ACS administration-to-
birth interval and survival. 
Results: We found a dose-dependent association between number of ACS-courses and 
restricted body size at birth (study I). There was no clear correlation between repeat courses 
of ACS in fetal life and cardiometabolic risk factors at 14-26 years of age (study II). In 
addition, there was no indication that repeat ACS exposure had an adverse impact on 
cognitive function or psychological health at follow-up in adolescents and young adults 
(study III). In study IV we found a significant reduction in mortality among extremely 
preterm infants after any ACS, with an optimal administration-to-birth interval of 1-7 days. 
Conclusions: Although exposure to repeat courses of ACS in utero were found to be related 
to gradually reduced body size at birth (indicating fetal growth restriction), it seems less 
likely from our findings that there are clinically important and long-standing adverse effects 
on cardiovascular and neuropsychological health. Another conclusion from this thesis is that 
ACS effectively reduces the mortality risk in extremely preterm infants and that timing of 
antenatal corticosteroids is important also in women delivering extremely preterm. 
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1 BACKGROUND 
1.1 PRETERM BIRTH 
1.1.1 Definition and epidemiology 
The duration of a normal human pregnancy is 40 weeks or 280 days from the first day of last 
menstrual period.1 The currently accepted definition of preterm birth is birth before 37 
completed weeks of pregnancy, very preterm before 32 weeks and extremely preterm before 
28 weeks of pregnancy (figure 1).2  
 
week 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 
 Extremely preterm 
<28 w 
                
 Very preterm <32 w 
 
            
 Preterm <37 w 
 
       
                Term 37-41 w 
 
  
                     Postterm 
42 w+ 
 
Figure 1. Definition of preterm birth (adapted from Tucker et al.2) 
 
According to the World Health Organization (WHO), about 15 million babies are born 
preterm each year, which is more than 1 in 10 babies. In almost all countries the preterm birth 
rates are increasing. About 1 million babies die each year due to complications of preterm 
birth, making prematurity the leading cause of death in children under the age of 5 globally.3  
In Sweden the preterm birth rates look slightly different. 6% of all babies are born preterm 
(<37 weeks), about 1% are born very preterm (<32 weeks) and approximately 0.3% are born 
extremely preterm (<28 weeks).4 Compared to many other countries the preterm birth rates 
have been rather stable during the last decades.4  
1.1.2 Survival after preterm birth 
The survival rate after preterm birth in Sweden is also different from the global rates. 
Survival among moderately preterm and very preterm babies in Sweden is almost universal 
and survival rate after extremely preterm birth is steadily improving. The one-year survival 
after being born alive at extremely preterm gestational age in Sweden is now approximately 
70%5,6 compared to the early 90´s when the corresponding rate was about 40%7 (figure 2). 
The causes for the improved survival are related to many factors in modern obstetric and 
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neonatal care. The use of antenatal corticosteroids (ACS), exogenous surfactant, advanced 
ventilator strategies and the centralization of neonatal intensive care are some factors that 
have contributed greatly to the improved outcome after preterm birth. However, the improved 
survival must be put in relation to the neonatal morbidity following preterm birth. 
 
Figure 2. Survival rates after extremely preterm birth in Sweden 1990-19927, 2004-20075 and 
2007-20156 
 
1.1.3 Neonatal morbidities of preterm birth 
Infants who are born preterm face an increased risk of neonatal morbidity compared to 
infants born at term. Most organs are immature in preterm babies leading to a diversity of 
neonatal illnesses including respiratory distress syndrome (RDS), bronchopulmonary 
dysplasia (BPD), brain injuries such as intraventricular haemorrhage (IVH) and 
periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), retinopathy of 
prematurity (ROP), nutritional difficulties, hyperbilirubinemia, renal failure, invasive 
infections, persisting fetal circulation and patent ductus arteriosus (PDA). One way to get an 
early indication of possible long-term outcome following preterm birth is to measure major 
neonatal morbidities. The major morbidities are often referred to as; IVH grade III or more, 
cystic PVL, NEC, ROP stage 3 or more, and severe BPD. The risk of major neonatal 
morbidities will increase with lower gestational age (GA) as will the risk of poor long-term 
outcome.8 The incidence of the major morbidities varies in different settings. In Sweden the 
chance of surviving one year without any major neonatal morbidity after extremely preterm 
birth ranged from 2% at 22 weeks of gestation to 54% at 26 weeks (figure 3).5  
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Figure 3. One-year survival without major neonatal morbidity in Sweden 2004-20075     
  
1.2 ANTENATAL CORTICOSTEROIDS (ACS) 
One of the most important interventions for improving survival and decreasing morbidity 
after preterm birth is to treat pregnant women with threatening preterm delivery with 
antenatal corticosteroids (ACS). In 1972, drs Liggins and Howie conducted a randomized 
controlled trial (RCT) demonstrating that treatment with ACS markedly reduced the risk of 
infant respiratory distress syndrome and neonatal mortality.9 This has since then been 
confirmed in numerous studies.10,11 ACS have in addition to its effect on pulmonary 
maturation been proved to reduce the risk of intraventricular hemorrhage, early systemic 
infections and necrotizing enterocolitis.11 ACS reduces the overall risk of neonatal death with 
an average of 31% (RR 0.69; 95% CI 0.59-0.81).12 The morbidities ameliorated by ACS are 
described in more detail below (chapter 1.2.3).   
1.2.1  Recommendations for ACS treatment 
Antenatal corticosteroids are widely recommended worldwide because of its proven 
beneficial effects on neonatal outcome after preterm birth. The latest Cochrane review from 
2017 concludes that a single course of antenatal corticosteroids should be considered routine 
for preterm delivery.12 The World Health Organization recommends ACS for women at risk 
of preterm birth from 24 weeks to 34 weeks of gestation.13 The latest guidelines from the 
American College of Obstetricians and Gynecologists (ACOG) state that a single course of 
corticosteroids is recommended for pregnant women between 24 0/7 weeks and 33 6/7 weeks 
of gestation.14 The UK National Institute for Health and Care Excellence (NICE) published 
their latest guidelines 2015 in which they recommend offering ACS between 26 0/7 and 33 
0 
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6/7 weeks of gestation.15 In Sweden, the current recommendations are to treat pregnant 
women with threatening preterm labour between 23 0/7 and 33 6/7 weeks of gestation.  
The most used treatment regimen is two doses of 12 mg of betamethasone (BM) 
intramuscularly 24 hours apart. This regimen is one example of a complete course of ACS. 
When only one of the two doses has been administered before birth, it is referred to as an 
incomplete course. In a minority of settings, dexamethasone (DX) is used instead of 
betamethasone and there are still insufficient evidence to support the use of one corticosteroid 
over the other.12 
The well-described positive effects of ACS have though been accompanied by concerns 
regarding potential adverse effects on the fetus, affecting both short- and long-term health. 
Those concerns have mainly risen from in vitro studies and studies in animals, showing 
unwanted side effects on different tissues and organs. Concern for side effects of ACS are of 
particular concern in pregnancies that do not end preterm. In such cases, little if any benefit 
from ACS may be outweighed by potential adverse effects. 
1.2.2  Corticosteroid´s mechanism of action 
To be able to understand how ACS can exert their positive, and potential negative, effects on 
the fetus we have to look at the function of glucocorticoids in general. 
1.2.2.1  Glucocorticoids during pregnancy  
The main circulating 
endogenous 
glucocorticoid (GC) in 
humans is cortisol. 
Cortisol is produced and 
released from the adrenal 
cortex. This is regulated 
by the hypothalamic-
pituitary-adrenal axis 
(HPA-axis) (figure 4). 
 
 
 
 
 
Figure 4. The hypothalamic-pituitary-adrenal axis (HPA-axis) 
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Glucocorticoids are involved in the expression of a large variety of genomes in many organ 
systems and they regulate metabolic processes and stress responses.16 Their pharmaceutical 
use derives from their anti-inflammatory and immunosuppressive activities.  
Glucocorticoids play a very important role in the normal fetal development, especially 
regarding pulmonary maturation, brain development and fetal growth (see chapter 1.4.2.2). 
Nevertheless, excessive transmission of glucocorticoids to the immature fetus could have a 
negative impact on developmental programming, narrowing physiological boundaries for 
health and increasing the risk of subsequent disease later in life (see chapter 1.4.2.3).17 During 
pregnancy, the fetus is protected from high levels of endogenous cortisol from the mother via 
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in the placenta and fetal tissue. 11β-
HSD2 converts active cortisol to inactive cortisone and prevents the entry of maternal cortisol 
to the fetal compartment. In addition, the HPA-axis in the immature fetus is inactivated which 
results in low fetal output of cortisol. Hence, the fetal levels of cortisol are approximately 
10% of those in maternal blood.16 In contrast, the synthetic glucocorticoids betamethasone 
and dexamethasone used in ACS treatment, are not inactivated by 11β-HSD2, which results 
in higher concentrations of synthetic glucocorticoids in fetal blood (30% of those in maternal 
blood).16 
Endogenous glucocorticoids exert their effects mainly through the glucocorticoid receptor 
(GR) but also through the mineralocorticoid receptor (MR), which act as transcription factors 
to alter gene expressions. In addition, GR and MR can also mediate fast non-genomic actions 
via membrane-located receptors.18 The synthetic GCs BM and DX only have affinity to the 
glucocorticoid receptor and bind to the GR with 25-fold higher affinity than cortisol.19   
1.2.2.2 Glucocorticoids and normal fetal development 
One of the most vital roles of glucocorticoids in the normal fetal development is their effects 
on pulmonary maturation, lowering the risk of respiratory distress in preterm infants (chapter 
1.2.3.1).  Glucocorticoids also play a vital role in fetal brain development by initiating 
terminal neuronal maturation, remodeling of axons and dendrites and affecting cell 
survival.20,21 Besides its effects on the fetal lungs and brain, GC have important effects on 
other organ systems such as the heart, circulation, kidneys, liver, adipose and thyroid, all 
contributing to improve postnatal adaptation.17,22 Glucocorticoids also affect systems that 
regulates fetal growth23 and profoundly influence the development and lifelong function of 
the HPA-axis.24 
1.2.2.3 Glucocorticoids and developmental programming 
The ability of the early environment to program physiological function throughout life was 
identified already in the 1950s.25 In the 1980s, Barker et al discovered that low birth weight 
was associated with increased risk of cardiovascular disease in adulthood.26 He postulated 
that low birth weight could be seen as a surrogate marker of fetal malnutrition, and that there 
was a causative relationship between adverse fetal environment and suboptimal health in 
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adulthood. Since then, animal experiments as well as observational human data has provided 
support for the Barker hypothesis.27-29 This field of research, exploring the association 
between environmental challenges during pregnancy, altered fetal growth and development, 
and later pathophysiology, is referred to as the developmental origins of health and disease or 
developmental programming. 
Glucocorticoids are, as mentioned above, an important developmental switch, driving 
changes in gene regulation that are necessary for normal fetal growth and maturation of many 
organ systems. However, excessive transmission of GC to the fetus or at an incorrect stage of 
maturation have been suggested to be major contributing mechanisms for adverse 
developmental programming, resulting in altered physiological function throughout life.17,30,31 
Synthetic glucocorticoids effect on the HPA-axis is of special concern since the HPA-axis has 
a critical role in the regulation of metabolic, cardiovascular, reproductive and neurological 
systems, and dysregulation of the HPA-axis is associated with a number of chronic 
diseases.17,32-34             
1.2.3 Neonatal morbidities affected by ACS 
1.2.3.1 Respiratory distress syndrome (RDS) 
RDS is one of the most serious complications of preterm birth and the primary cause of early 
neonatal death.35 It affects up to 80-90% of extremely preterm infants and about half of the 
very preterm infants, but can also affect infants born at later gestations.36 RDS usually 
presents at birth or shortly thereafter. The symptoms are progressive and include grunting, 
chest wall retractions, nasal flaring, and increased work of breathing. In the infant lung, 
surfactant is produced by type II pneumocytes in the alveolar airspaces. Surfactant forms a 
film in the alveoli, lowering alveolar surface tension thus increasing lung compliance and 
preventing atelectasis. The pathophysiology behind the disease can briefly be explained by 
the structurally immature and surfactant-deficient lung that has a tendency to collapse. The 
presence of relatively well-perfused but poorly ventilated areas of the lung results in 
ventilation/perfusion mismatch with hypoxemia and hypercarbia. Left untreated, the 
condition may lead to respiratory failure and death. The treatments for RDS include 
surfactant replacement therapy, continuous positive airway pressure (CPAP), and mechanical 
ventilation.  
The use of ACS to enhance pulmonary maturation has markedly reduced the incidence of 
RDS. Reviews have shown that ACS reduces the risk of RDS with an average of 34% (RR 
0.66; 95% CI 0.56-0.77) and the need for mechanical ventilation with an average of 32% (RR 
0.68; 95% CI 0.56-0.84).12 
The mechanism behind ACS´ positive effect on the fetal lung is that glucocorticoids increase 
surfactant production by increasing phospholipid synthesis and stimulating the production of 
surfactant-associated proteins.37 In addition, GCs promote fetal lung development by 
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stimulating cell maturation and differentiation, stimulating antioxidant enzymes, thinning of 
the alveolar septae and regulating pulmonary fluid metabolism.37-39  
1.2.3.2 Intraventricular hemorrhage (IVH) 
The risk of developing IVH is inversely proportional to gestational age. It mainly affects 
preterm infants born before 32 weeks. The incidence ranges from about 10-50% in different 
centers. 90% of the cases occur in the first 3 days after birth. IVH is a hemorrhage from the 
germinal matrix located in the lateral ventricles of the brain. The hemorrhage is commonly 
graded I-IV where grade I is a small hemorrhage in the subependymal area or in the matrix, 
grade II includes blood in the ventricle but without ventricular dilatation, grade III includes 
ventricular blood with ventricular dilatation whereas grade IV includes parenchymal 
engagement.40 The prognosis for IVH grade I-II is generally considered good whereas 
grade III and IV increase the risk of poor neurological outcome such as cerebral palsy (CP), 
lower cognitive function and impaired motor function41 and is associated with white matter 
damage (PVL).41,42  
The use of ACS has in systematic reviews been found to reduce the incidence of IVH with 
an average of 45% (RR 0.55; 95% CI 0.40-0.76).12 
Glucocorticoids role in prevention of IVH is likely due to increased circulatory stability and 
vascular resistance,43,44 maturation of cerebral microvasculature45,46 and improved lung 
function reducing the need for mechanical ventilation. 
1.2.3.3 Necrotizing enterocolitis (NEC) 
NEC is a rare but potentially very serious complication after preterm birth. It is an 
inflammatory condition in the gut mainly affecting the most immature infants or infants 
small for gestational age (SGA). The incidence varies from about 5-10% in different 
settings. The etiology is not fully understood but some predisposing factors are enteral 
feeding, decreased oxygenation of the gut, decreased intestinal blood flow and invasion of 
pathogenic bacterial flora. The clinical symptoms include a distended abdomen, blood in 
the stools and signs of pain in the infant. The disease is characterized by acute 
inflammation of the intestinal wall, necrosis, perforations and septicemia. Milder cases are 
often treated conservatively with antibiotics and withheld feeds whereas more severe cases 
require surgical intervention. Mortality rates can be up to 50% in severe cases.47  
The use of ACS has been found to reduce the incidence of NEC with an average of 50% 
(RR 0.50; 95% CI 0.32-0.78).12 
1.2.3.4 Neonatal infections 
Systemic infections are common complications after preterm birth and can be divided into 
two subgroups; early onset (within 48 hours after birth) and late onset (>48 hours after 
birth). The incidence of septicemia in extremely preterm infants varies from 25-60%.48 
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Early neonatal infections are mainly contracted in utero or at birth and the most common 
microorganisms are group B streptococci. Late onset infections are mainly nosocomial and 
the most common microorganism is coagulase-negative staphylococci. Systemic infections 
are treated with antibiotics and antibiotic treatment is often given on wide indications 
before bacterial infection can be excluded.  
The use of ACS has been found to reduce the incidence of early systemic infections with an 
average of 40% (RR 0.60; 95% CI 0.41-0.88).12 
1.2.4 Long-term outcomes of preterm birth  
1.2.4.1 The Barker hypothesis 
In addition to the increased neonatal morbidity, survivors after preterm birth also face an 
increased risk of illness later in life. Barker et al discovered in the 1980´s that low birth 
weight as a surrogate marker of adverse fetal environment, was associated with increased risk 
of cardiovascular disease in adulthood.26 This has then been observed in numerous studies 
and it is now widely known that both low birth weight and prematurity are predisposing 
factors for developing pulmonary, cardiovascular and metabolic diseases as well as 
neurological and neurodevelopmental conditions later in life. Besides fetal malnutrition, 
excess exposure to glucocorticoids in utero could be a candidate mechanism underlying the 
associations between low birth weight and increased risk of cardiometabolic and other 
diseases in adulthood. 
1.2.4.2 Cardiovascular and metabolic outcome after preterm birth 
Most studies reporting data in historical cohorts before the modernization of perinatal and 
neonatal medicine show no increased risk for coronary heart disease or hypertension among 
elderly people born preterm.49,50 However, these results are biased because of the very 
selective survival after preterm birth during that time period. In the modern era of perinatal 
and neonatal medicine (after the 70´s) with a more universal survival, there are emerging 
numbers of studies showing an association between prematurity and increased risk of 
cardiovascular and metabolic diseases later in life. For example, preterm birth has been 
correlated to hypertension51-53, altered structure and function of the heart and the arterial 
tree54,55, diabetes56,57, increased levels of plasma low-density lipoproteins (LDL)53, 
overweight58 and stroke59,60 in adults.  
Since most women delivering preterm nowadays receive ACS, antenatal corticosteroid 
exposure could be one explanatory factor for these associations. In animals, ACS exposure 
has been associated with increased risk factors for cardiometabolic disease including 
enhanced fat deposition,61 impaired metabolism of visceral fat,62 higher blood pressure63 and 
decreased insulin sensitivity.64 In contrast to animal studies, the adverse effects of ACS in 
humans appear to be less prominent. A long-term follow-up in adult subjects has found that 
those exposed antenatally to synthetic GCs compared with placebo had similar blood 
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pressure, adiposity, blood lipids, fasting insulin concentrations, glucose tolerance and 
morning cortisol concentrations.65 Results from human observational studies have been a bit 
conflicting, with some showing no association between ACS exposure and later risk factors 
for cardiometabolic disease,66,67 while others have showed a small increase in blood 
pressure,68 slight decrease in renal clearance66, impaired β -cell function and evidence of 
increased aortic stiffness.69 In addition, two observational studies demonstrated increased 
stress reactivity in term-born children exposed antenatally to glucocorticoids.70,71 
1.2.4.3 Neurodevelopmental outcome 
It is well known that survivors of preterm birth face an increased risk of impaired 
neurological function. Major neurological disabilities such as cerebral palsy (CP), hearing 
and visual impairment are often used as markers for quality of care but cognitive difficulties 
and behavioral problems are also important outcome measures. Neurodevelopmental 
disability (NDD) is often categorized into mild, moderate or severe depending on the status of 
hearing, vision, IQ and Gross Motor Function Classification System (GMCFS). The 
incidence of NDD varies greatly between countries. A recent meta-analysis including studies 
from eight developed countries showed that the proportion of moderate to severe NDD 
among survivors of preterm birth ranged from 43% in infants born at 22 weeks of gestation to 
24% in infants born at 25 weeks of gestation.72 In the Swedish EXPRESS-cohort born before 
27 weeks of gestation, the incidence of moderate to severe NDD at 6.5 years of age was 
34%.73  
Major neurological disabilities are often identified early in life whereas milder deficits 
affecting behavioral, intellectual and educational outcome may become obvious with 
increasing age. These more subtle cognitive dysfunctions reported in children born preterm 
include lower intelligence, visual motor problems, deficient memory, delayed language skills, 
executive dysfunctions and social and emotional difficulties.74 Increased prevalence of 
learning disabilities, ADHD and autism spectrum disorders have also been reported.75  
In animal studies, exposure to ACS has been associated with reduced brain mass,76,77 delayed 
myelination, decreased maturation of the retina and peripheral nerves78,79 and impaired 
programmed apoptosis.80 Some of these effects persisted into adulthood,81 raising concerns 
that ACS treatment could contribute to adverse long-term neurodevelopment in individuals 
born preterm. However, in human studies, the outcomes after ACS exposure are much more 
reassuring. In RCTs, there are no significant correlation between ACS and adverse effects on 
later cognitive ability or neurosensory disability, including cerebral palsy.82,83 84,85 Other 
results in human studies are contradictive. For example, several studies have suggested 
adverse effects on emotional regulation after ACS exposure,86,87 whereas in longer term 
follow-up of clinical trials there have been no correlation to clinically significant disturbances 
in early childhood behavior, executive function or adult psychiatric illness.84,88,89 
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1.2.4.4 Pulmonary outcome 
The most severe pulmonary complication after preterm birth is the development of 
bronchopulmonary dysplasia (BPD). BPD is often defined by the need of supplemental 
oxygen at 36 weeks postmenstrual age and is graded into mild, moderate or severe depending 
on how much oxygen needed. The risk of developing BPD increases with decreasing GA, 
prolonged mechanical ventilation and oxygen therapy. BPD is a combined restrictive and 
obstructive disease where the restrictive component tends to normalize during the first years 
whereas the obstructive component tends to predominate later in life with asthma-like 
symptoms.90,91 Severe cases will be dependent on supplemental oxygen for several months to 
years. Individuals being born preterm but with no or only mild BPD also have an increased 
risk of respiratory symptoms and decreased lung function later in life than the general 
population.92-94 
Although ACS has many beneficial effect on the fetal lung, some experimental studies in rats 
exposed to ACS have shown a correlation to larger and fewer alveolar air spaces in 
adulthood,95,96 raising concern that later lung growth may be impaired also in humans. 
However, in clinical studies, ACS exposure did not affect spirometric measures of lung 
volume or expiratory flow in childhood and adulthood.97 98 
1.2.5 Repeat courses of ACS 
Although the beneficial effects of ACS on the fetus are very well described, many studies 
have suggested a transient effect from ACS. 9,11,99 It seems like the maximum benefit from 
ACS on the fetus occurs 24 hours to 7 days after a complete course has been given. After 7 
days the positive effects have diminished. This suggests that timing of ACS administration is 
crucial. Diagnosing actual preterm labour has been proved to be difficult, with 30-80% of 
women with symptoms suggesting preterm labour remaining pregnant 14 days later.100,101 
This has raised the question whether or not to repeat the ACS course to women who remains 
undelivered 7 days after the initial course. In Danderyd hospital, Stockholm, Sweden, and 
many other settings, it was routine during the 1980´s and 90´s to repeat the ACS course 
weekly to undelivered women with threatening preterm delivery until delivery occurred or 
until pregnancy reached 34 weeks. In some settings a rescue course of ACS is used, meaning 
administering a second course to patients whose pregnancies continue more than a week or 2 
beyond their original course and in whom delivery has again become likely.102 Studies have 
shown that repeat courses of ACS add positive effects on neonatal outcome compared to a 
single course. The latest Cochrane review from 2015 found that repeat courses of ACS to 
pregnant women still undelivered 7 days after an initial course was associated with 17% 
reduction in RDS and 16% reduction in serious infant outcome and the absolute benefit of 
repeat doses was similar to that of an initial course (numbers needed to treat to prevent 
respiratory distress syndrome: single course 12; repeat courses 17).103  
The suggested beneficial effects from repeat courses of ACS must however be put in relation 
to the concerns of potential negative effects from excess glucocorticoid exposure on fetal 
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growth and development, as well as long-term health. The rationale for these concerns mainly 
rises from results from experimental animal studies, showing that repeat courses of ACS 
could have negative effects on a variety of functions including fetal growth104, brain 
development81, behaviour105, vascular function106, fat/glucose metabolism107,108 and HPA-
function104. In human studies however, the effects from repeat courses of ACS appears to be 
less harmful: 
1.2.5.1 Effects on fetal growth after repeat courses of ACS 
Some studies in humans have shown a reduction in fetal growth after repeat courses of 
ACS109-112 whereas others have not113,114. Reductions in both birth weight, birth length and 
head circumference at birth have been reported. However, the observed reductions in some 
measures of growth seems to be transient with the observed differences in birth size no longer 
significant at hospital discharge112 or at later follow-up of the child87,115. Furthermore, many 
of the studies where a difference in birth size has been observed have not adjusted for 
gestational age, making the results difficult to interpret.103  
Several mechanisms have been suggested to contribute to the glucocorticoid-induced 
retardation of fetal growth. These include altered placental function and nutrient transfer,116 
decreased DNA synthesis and cell division,117 reduced fetal tissue water content118 and 
increased protein catabolism.119 It is likely that altered expression and action of insulin-like 
growth factors (IGF) underlie many of these changes.120 
1.2.5.2 Long term outcome after repeat courses of ACS 
The largest randomized controlled studies investigating the effects of repeat courses of ACS 
have reported outcomes in early childhood (2-8 years) and the results are reassuring.87-
89,115,121,122 As shown in table 1, there is no increased risk for any of the reported outcomes 
following repeat courses of ACS. However, one large American RCT reported higher rates of 
CP in the repeat group (five of six cases), although not statistically significant (p=0.12).115 In 
addition, the Australasian RCT reported that more individuals in the repeat group were 
assessed for attention problems than in the single course group at the 2-year follow-up.87 At 
the follow-up at 6-8 years of age there were however no reported differences in 
neurodevelopmental outcome (table 1).121 
Follow-ups into adolescence and adulthood are however lacking and there is a concern that 
possible negative effects of excessive glucocorticoid exposure could be revealed later in life. 
The latest Cochrane review states that there is a need for follow-up studies into adulthood 
after repeat courses of ACS.12 
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Table 1. Outcomes after repeat courses of ACS reported in randomized controlled trials. Red 
text indicates adverse outcomes, arrows indicate direction of an effect after repeat ACS courses versus 
a single course. 
Author/group Neonatal outcome Outcome at follow-up 
Asztalos et al/ 
MACS 
(Multiple Courses 
of Antenatal 
Corticosteroids 
Study) 
 
• Mortality, severe RDS, IVH 
3-4, PVL, BPD, NEC è 
• Birth weight, birth length, 
head circumference ê 
2 years 
• Death, neurologic impairment 
è 
5 years 
• Death, survival with 
neurodevelopmental 
disability è 
Crowther et al/ 
ACTORDS 
(The Australasian 
Collaborative Trial 
of Repeat Doses of 
Corticosteroids) 
• RDS, severe lung disease, 
oxygen therapy, mechanical 
ventilation ê 
• Birth weight, head 
circumference ê - no 
difference at discharge from 
hospital 
2 years 
• Body size, blood pressure, 
respiratory morbidity, 
behavior score, survival free 
of major morbidity è 
• Assessed for attention 
problems é      
6-8 years 
• Body size, fat mass, blood 
pressure, spirometry, insuline 
sensitivity, estimated GFR, 
neurodevelopment, cognitive 
function, behaviour, health-
related quality of life, use of 
health services è 
Wapner et al • Surfactant administration, 
mechanical ventilation, 
CPAP ê (≥4 courses) 
• Birth weight ê (≥4 courses) 
• Small for gestational age é 
• Composite neonatal outcome 
è 
2-3 years 
• Body size, neurocognitive 
function tests è 
• (Cerebral palsy é (p=0.12)) 
 
Peltoniemi et al • RDS é  2 years 
• Survival without severe 
developmental impairment, 
cerebral palsy, growth, 
rehospitalisation è 
è = no difference, ê = decreased, é = increased 
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1.2.5.3 Recommendations about repeat courses of ACS 
The clinical recommendations regarding use of repeat courses of ACS are diverging as 
illustrated in figure 5. More studies about the effects and possible adverse outcomes after 
repeat courses of ACS are warranted before a more conclusive recommendation can be 
stated.  
 
 
Figure 5. Recommendations about repeat courses of ACS 
? 
Cochrane review 2015: 
“The short-term benefits for 
babies of less respiratory 
distress and fewer serious 
health problems in the first few 
weeks after birth support the 
use of repeat courses of ACS 
for women still at risk of 
preterm birth seven days or 
more after an initial course. 
These benefits were associated 
with a small reduction in size 
at birth. The current available 
evidence reassuringly shows no 
significant harm in early 
childhood, although no 
benefit.”67  
ACOG recommendations  
2016: 
“A single repeat course of 
antenatal corticosteroids should 
be considered in women who 
are less than 34 0/7 weeks of 
gestation who have an imminent 
risk of preterm delivery within 
the next 7 days, and whose prior 
course of antenatal 
corticosteroids was 
administered more than 14 days 
previously. Rescue course 
corticosteroids could be 
provided as early as 7 days from 
the prior dose, if indicated by 
the clinical scenario. Regularly 
scheduled repeat courses or 
serial courses (more than two) 
are not currently 
recommended.”57  
NICE guidelines 2015: 
”Do not routinely offer 
repeat courses of 
maternal 
corticosteroids, but take 
into account: the 
interval since the end of 
last course, gestational 
age and the likelihood of 
birth within 48 hours.”58  
WHO guidelines 2015: 
“A single repeat course of 
antenatal corticosteroid is 
recommended if preterm 
birth does not occur within 7 
days after the initial dose, 
and a subsequent clinical 
assessment demonstrates 
that there is a high risk of 
preterm birth in the next 7 
days.”56 
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1.2.6 ACS in extremely preterm gestations 
Most studies evaluating the effect of ACS on neonatal outcome have been conducted in 
moderately preterm or very preterm gestations. There are very sparse data on ACS´s effects 
in extremely preterm gestations. It is important to note that the evidence supporting ACS at 
<26 weeks gestation is based mainly on laboratory studies and non-RCTs. The only RCT in 
this field is from the pre-surfactant era and only had 49 participants in that group.9 A previous 
meta-analysis evaluating ACS in extremely preterm gestations showed no reductions of 
neonatal mortality and morbidity prior to 26 weeks gestation123 whereas more recent studies 
have indicated similar124,125 or even more pronounced benefits126,127 from ACS for extremely 
preterm births. In a Swedish population-based prospective observational study of extremely 
preterm infants born 2004-2007 (EXPRESS), ACS-treatment was associated with a 
significantly lowered mortality (OR=0.4; 95% CI=0.2-0.8).5 In the same study they showed 
that ACS is a very common treatment also among extremely preterm infants (Figure 6). This 
is however not true for many other settings where treatment with ACS in extremely preterm 
gestations is more restricted. For example, in the French EPIPAGE-2 cohort study with 
extremely preterm infants born in 2011, only 2% of neonates at 22 weeks, 12% at 23 weeks, 
57% at 24 weeks and 78% at 25 through 26 weeks gestation were treated with ACS (figure 
6).128 The reason to refrain from ACS treatment at extremely low gestations most likely 
reflect an anticipation of a very poor prognosis in which case ACS would not be administered 
and management of the infant after birth would be limited to compassionate care. But another 
explanation could be that use of ACS at the lower end of gestations was judged as pointless. 
 
Figure 6. ACS treatment among extremely preterm infants in Sweden 2004-2007 (EXPRESS)5 
and in France 2011 (EPIPAGE-2)128 
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The most recent recommendations for ACS treatment include the possibility to treat even 
more immature infants. The ACOG recommendations from 2016 states that ACS may be 
considered for pregnant women starting at 23 0/7 weeks of gestation who are at risk of 
preterm delivery within 7 days, based on a family’s decision regarding resuscitation.14 The 
NICE guidelines also states that ACS could be considered from week 23 0/7.15 In the new 
Swedish national guidelines from 2016, ACS should be considered from 22 0/7 weeks of 
gestations. 
1.2.7 Are the recommendations implemented? 
Knowing the recommendations on ACS treatment, one can ask how well the 
recommendations are implemented in clinical practice. In a recent European study, the use of 
ACS varied greatly between different European settings. The proportion of pregnant women 
delivering at 24-32 weeks gestation, receiving ACS varied between 70 and 98% (figure 7).129 
 
 
Figure 7. Treatment rates of antenatal corticosteroids (ANS) in European settings129  
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Recent corresponding figures from the US show that an average of 69.4% of infants born 
from 23 0/7 to 34 6/7 weeks gestation had been exposed to ACS.127 Rates of exposure to 
ACS were lower among infants at the higher and the lower ends of the recommended 
gestational age range (figure 8). 
 
 
Figure 8. Treatment rates of antenatal corticosteroids by gestational age in the United States127 
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2 AIMS OF THE THESIS 
The overall objective with this thesis is to investigate the safety and efficacy of antenatal 
corticosteroids in both a short and long term perspective. 
The specific aims of the included studies are: 
Study I: 
• To investigate if the effects of ACS on birth size are dose dependent.  
• To investigate if the length of gestation at start of ACS therapy is correlated to birth size. 
Study II: 
• To investigate the relationship between repeat courses of ACS and risk factors for 
cardiovascular and metabolic disease in adolescents and young adults. 
Study III: 
• To investigate the relationship between repeat courses of ACS and cognitive and 
psychological functioning in adolescents and young adults.  
Study IV: 
• To investigate the impact of the administration-to-birth interval of ACS on survival of 
exremely preterm infants 
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3 METHODS 
3.1 STUDY DESIGN 
Figure 9 presents an overview of the included studies. The two cohorts will be described 
thoroughly in the next chapter. All studies in the thesis are cohort studies. 
 
 
 
Figure 9. An overview of study I-IV 
 
 
 
The FAST 
cohort 
born 1983-1996 
moderately preterm 
Exposure: various 
courses of ACS 
STUDY I 
Outcome: size at 
birth  
STUDY II 
 Outcome: risk 
factors for 
metabolic and 
cardiovascular 
disease at 14-26 
years of age 
STUDY III 
Outcome: 
neuropsycho-
logical function 
at 14-26 years of 
age 
The EXPRESS 
cohort 
born 2004-2007 
extremely preterm 
Exposure: ACS at 
different time-intervals 
before birth 
 
STUDY IV 
Outcome: neonatal 
and infant mortality 
and major neonatal 
morbidity  
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3.2 STUDY POPULATIONS 
3.2.1 The FAST cohort  
The Fetal Antenatal Steroid Treatment (FAST) study was a cross-disciplinary venture 
assessing both psychological and medical aspects after corticosteroid exposure in utero. All 
subjects in this cohort were born at Danderyd Hospital, Stockholm, Sweden, between the 
years 1983 and1996. This hospital was among the first in Sweden implementing the use of 
ACS to pregnant women with threatening preterm delivery. During the study period, standard 
ACS treatment consisted of an initial induction of betamethasone 24 mg intramuscular (8 mg 
x 3 with 8 hour intervals), followed by a weekly course of 12 mg betamethasone, continued 
until delivery or until pregnancy reached 34 gestational weeks, if the threat of preterm 
delivery still remained. This treatment regimen is referred to as multiple or repeat courses of 
ACS. All infants exposed to repeat courses of ACS were eligible for inclusion in the study. 
Predefined exclusion criteria were fetal anomalies, maternal steroid use for other medical 
conditions, congenital viral infections and chromosomal aberrations. Infants exposed to 
repeat courses of ACS in utero (two to nine courses) were categorized into three groups 
depending on the number of exposures (figure 10).  
 
Figure 10. Flow chart of the FAST cohort 
 
The majority of the infants in the cohort were born moderately preterm or term (mean 
gestational age 34.0 weeks) and with no major neonatal complications (table 2). During the 
study period, pregnant women were offered free healthcare visits throughout the pregnancy, 
and almost all (98%) attended their midwife appointments. Further description of the cohort 
is found in paper I-III. 
 
 
 
repeat courses 
n = 94 
2 courses 
n = 28 
3 courses 
n = 26 
≥ 4 courses 
n = 40  
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Table 2. Neonatal characteristics of the FAST-cohort 
 2 courses 
n = 28 
3 courses 
n = 26 
≥ 4 courses 
n = 40 
Mean gestational age, w 34.9 33.2 34.4 
Mean birth weight, g 2381 2192 2292 
Boys, n (%) 15 (54) 18 (69) 26 (65) 
IVH/PVL, n (%) 0 0 0 
NEC, n (%) 0 0 0 
ROP, n (%) 0 1 (4) 0 
BPD, n (%) 0 1 (4) 1 (3) 
 
3.2.2 The follow-up studies (II & III) 
For the follow-up of the FAST-cohort, four of the 94 subjects could not be found or had 
moved from Sweden. The remaining 90 were invited to participate in the follow-up, 58 
accepted and completed the assessment. At follow-up, participants´ ages ranged from 14-26 
years with a mean age of 18 years, 62% were boys.  
A control group of individuals unexposed to ACS and matched for gestational age, sex and 
year of birth were identified from the same hospital´s birth registry. Of the 103 controls 
invited to follow-up, 44 accepted and completed the assessment. For dose-response analyses, 
we also included a group of subjects exposed to a single course of ACS by using the same 
criteria as for the control group. Of the 48 subjects invited in this group, 25 accepted and 
completed the assessment. Figure 11 illustrates the included groups in the follow-up studies. 
 
 
Figure 11. Flow-chart of the participants in the follow-up studies  
EXPOSURE INVITED ASSESSED 
Multiple 
courses n = 90 n = 58 (64%) 
Single course n = 48 n = 25 (52%) 
Unexposed n = 103 n = 44 (43%) 
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3.2.3 The EXPRESS cohort (IV) 
The Extremely Preterm Infants in Sweden Study (EXPRESS) included all pregnant women 
residing in Sweden and delivering extremely preterm infants, born at 22–26 completed weeks 
of gestation, from April 1st 2004 to March 31st 2007. This cohort was used in study IV and 
consisted of all live-born infants (n = 707), including multiple births and infants with 
malformations, whereas stillborn infants (n = 304) were excluded. Among live born infants, 
520 survived the neonatal period and 497 were alive at 1 year old (figure 12). 
 
 
Figure 12. Flow-chart of the EXPRESS-cohort5 
 
In the EXPRESS-cohort, 84% were exposed to antenatal corticosteroids in utero. A complete 
course with ACS to the pregnant mothers consisted of two doses of 12 mg betamethasone 24 
h apart. In the EXPRESS-database, time from the first ACS dose to delivery in hours had 
been prospectively collected. We categorized all live-born infants into four categories 
according to the time-interval from the first ACS dose to delivery: <24 h; 24–47 h; 48 h to 7 
days; and >7 days (figure 13). Further description of the cohort characteristics is found in 
paper IV. 
 
Infants born extremely preterm in Sweden  
2004 - 2007 
n = 1011  
Liveborn 
n = 707 
Neonatal survival  
(alive at 28 days) 
n = 520 
Infant survival  
 (alive at 1 year) 
n = 497 
Stillborn 
n = 304  
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Figure 13. Categorization of ACS exposure in the EXPRESS cohort 
 
3.3 DATA COLLECTION 
3.3.1 Study I-III (FAST) 
During the study period, comprehensive data from all mothers undergoing antenatal care and 
infants admitted for neonatal care were prospectively collected in a hospital registry. From 
this registry, we identified all infants born between 1983 and 1996, admitted for neonatal 
care, and whose mothers had received multiple courses of ACS (n = 81). In addition, we 
scrutinized the records from the antenatal clinic, and in total, we identified 94 infants exposed 
to multiple courses of ACS. Information on maternal age, height, parity, multiple pregnancy, 
smoking habits as well as infant sex, birth weight  (BW), birth length (BL) and head 
circumference (HC) at birth were retrieved from the Swedish Medical Birth Register (MBR). 
All MBR data were validated by scrutinizing maternal and infant hospital records. Maternal 
blood pressure disease, gestational age and neonatal morbidity were also recorded from these 
records. Standard deviation scores (SDS) for birth size were calculated according to national 
reference data for normal fetal growth.130  
3.3.1.1 The Swedish Medical Birth Register (MBR) 
All birth units in Sweden report to the Medical Birth Register (MBR). The register contains 
information on more than 99% of all births in Sweden. The information is collected 
prospectively during pregnancy on standardized forms and forwarded to the register. 
Validation of the MBR has proved high quality.131 
3.3.2 Study IV (EXPRESS) 
The EXPRESS-study was a national collaboration where all obstetric and pediatric 
departments in Sweden participated. The study was descriptive with no attempts in the 
study framework to standardize treatment. During the study period, Sweden had seven 
healthcare regions, each served by a regional level III hospital. The general policy was to 
Liveborn  
n = 707 
no ACS  
n = 85 
ACS 
n = 591 
<24 h 
n = 149 
24-47 h 
n = 66 
48 h - 7 days 
n = 171 
>7 days 
n =103 
unknown 
timing 
n = 102 
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centralize extremely preterm deliveries to these regional hospitals. In each of the 7 health 
care regions, one obstetric and one pediatric study coordinator were responsible for data 
acquisition and quality control. Data on mothers and stillborn infants were collected at the 
time of delivery. Data on live-born infants were collected prospectively during the first 180 
days of hospitalization or until discharge or death. Mother and infant data were cross-linked 
with the Medical Birth Register to ensure accuracy. Information on infant deaths after 
discharge home until 1 year was obtained from the National Population Register. Data 
collection continued for all infants who were transferred between hospitals. All data were 
collected by local staff on standard study forms in accordance with a manual defining the 
variables. Regional data were electronically transmitted to a central database and again 
checked for quality and completeness.5 
 
3.4 CLINICAL ASSESSMENTS 
At the follow-up of the FAST-cohort 14 to 26 years after birth we assessed cardiovascular 
and metabolic functions (study II) as well as neuropsychological function (study III). The 
follow-up took place at Astrid Lindgrens Children´s Hospital in Stockholm, Sweden, from 
October 2008 to April 2010.  
3.4.1 Cardiovascular and metabolic assessment (study II) 
All cardiovascular and metabolic assessments were performed by one registered and trained 
research nurse. 
3.4.1.1 Anthropometric measures 
The participants´ weight, height and waist circumference were registered. From these 
measures, Body Mass Index (BMI) was calculated. Overweight, obesity and elevated waist 
circumference were defined (see details in paper II).  
3.4.1.2 Blood pressure 
After at least 5 minutes of sitting rest, systolic BP (SBP) and diastolic BP (DBP) were 
measured in the left arm with an appropriately sized arm cuff. Three consecutive measures 
were performed at 2-minute intervals, and mean SBP and DBP values were calculated. 
Elevated blood pressure was defined for the different age groups (see details in paper II). 
3.4.1.3 Pulse wave analyses 
A pulse wave analysis system was used together with applanation tonometry to noninvasively 
acquire the radial artery pressure waveforms. Central aortic waveforms were derived from 
those obtained from the radial artery using a validated data transfer algorithm. From the aortic 
waveforms, central aortic SBP and DBP were determined. Identification of early and late 
systolic peaks in the aortic pressure curve allows quantification of an augmentation index 
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(AI, %). The AI is related to the speed of the central and peripheral pressure wave reflections 
and an increasing AI reflects increasing arterial stiffness. The mean value of 3 recordings, 
each comprising 10 consecutive pressure waves, was taken. Elevated AI was defined as AI 
above 10% and 17% for men and women, respectively (see paper II for more details).  
3.4.1.4 Blood sample analyses  
From each participant, 5 mL blood was sampled to analyse glucose, insulin, triglycerides, 
cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), apolipoprotein 
A1 (Apo A1) and apolipoprotein B (Apo B), lipoprotein(a), and cortisol concentrations in 
plasma or serum. From these analyses, HDL/LDL-ratios and Apo B/Apo A1-ratios were 
calculated. All blood samples were morning fasting samples. 
Homeostatic model assessment (HOMA) is a method for assessing insulin resistance (IR) 
from basal fasting glucose and insulin. HOMA-IR was calculated using a HOMA-
calculator.132 
3.4.2 Neuropsychological assessment (study III) 
All neuropsychological tests were performed by one licensed and trained psychologist who 
was blinded to exposure group and gestational age at birth. The assessments were performed 
in the same room and at approximately the same time of the day for all participants. The 
entire assessment process lasted 2.5 to 3 hours. The neuropsychological tests were grouped 
into five broadly defined domains including; i) General cognitive ability; ii) Memory and 
learning; iii) Working memory; iv) Attention and speed; and v) Cognitive flexibility and 
inhibition. The last three domains reflect executive functions. The tests included in the 
neuropsychological test battery are presented in table 3. Measures on psychological health 
were obtained from self-report forms including the Achenbach Adult or Youth Self-reports, 
the World Health Organization´s screen for ADHD and a Quality of Life Inventory (QoLI). 
 
  
  33 
Table 3. Neuropsychological test battery. Tests listed in order of administration.  
Test Source Brief description Cognitive 
domain 
MOT, Motor 
Screening 
Cantab Screens for visual, movement and comprehension 
difficulties. 
 
RTI, Reaction 
Time 
Cantab Measures speed of response and movement and 5-
choice paradigms. 
Reaction time 
Attention 
RVP, Rapid 
Visual 
Processing 
Cantab Measures visual sustained attention and is a sensitive 
measurement of general performance. 
Attention 
SWM, Spatial 
Working 
Memory 
Cantab Measures the ability to retain spatial information and 
to manipulate items in working memory. 
Working 
memory 
SST, Stop 
Signal Task 
Cantab Uses staircase functions to generate an estimate of 
stop signal reaction time and measures the ability to 
inhibit a prepotent response. 
Response 
inhibition 
IED, 
Intra/Extra 
Dimensional 
Set Shift 
Cantab Measures rule acquisition, reversal featuring visual 
discrimination, attentional set formation, 
maintenance, shifting and flexibility of attention. 
Cognitive 
flexibility 
TMT, Trail 
Making Test 
D-KEFS Connect by drawing a line digits and letters in 
numeric/alphabetical orders. 
Cognitive 
flexibility 
Speed 
RAVL-R  Examiner reads a list of 15 words and participant 
repeat all words he/she remembers directly and after 
30 minutes. 
Verbal learning/ 
retention 
Block Design WISC The participant views a constructed model or picture 
and use blocks to re-create the design within a time 
limit. 
General ability 
(non-verbal) 
Vocabulary WISC/
WAIS 
The participant names or defines words of increasing 
difficulty. 
General ability 
(verbal) 
Coding  WISC The participant transcribes digit-symbol codes within 
a time limit. 
Attention 
Speed 
Digit Span WISC The participant repeats an increasing number of 
digits in the same and the opposite order. 
Working 
memory 
Symbol 
Search 
WISC The participant is asked to mark symbols within a 
time limit. 
Attention 
Speed 
Design 
Fluency 
D-KEFS The participant connects 5 dots with lines to create 
unique patterns within a time limit. 
Cognitive 
flexibility 
Verbal 
Fluency 
D-KEFS The participant lists as many words as possible 
within a time limit with given beginning letters and 
semantic categories (e g animals, boy names). 
Cognitive 
flexibility 
Cantab, Cambridge Neuropsychological Test Assessment Battery; D-KEFS, Delis-Kaplan Executive Function 
System; WISC, Wechsler Intelligence Scale for Children; WAIS, Wechsler Adult Intelligence Scale 
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3.5  STATISTICAL METHODS 
3.5.1 Study I 
Group differences were tested using ANOVA and chi-square test. Correlation coefficients 
and linear regression were used to study associations between ACS timing and dose, and 
outcomes. To adjust for possible confounders or covariates, we used multiple linear 
regression analyses. A p-value <0.05 in the final model was considered statistically 
significant. Group characteristics are presented as mean and standard deviations (SD) or 
proportions (%). Outcomes are presented as mean (95% confidence interval). Considering 
that this was an observational study we had to be cautious about interpretations of a causative 
relationship and although several confounders were controlled for in the analyses, 
confounding cannot be excluded. 
3.5.2 Study II and III 
To test for group differences we used chi-square test or Student´s t-test. Simple linear 
regression was used to study associations between GA at first exposure and outcomes. To 
adjust for possible confounders or covariates, we used multiple linear regression analyses. 
Binary outcome variables were analysed using logistic regression. A p-value <0.05 in the 
final model was considered statistically significant. Data are presented as numbers, 
proportions (%), or mean and standard deviations. With our given sample, we had a power of 
0.8 to detect a group difference of 0.56 or more (i.e., medium effect size). The small size of 
our cohort and the observational study design are limitations and the interpretation of results 
has been performed with caution. Furthermore, we cannot exclude selection bias in study 
participation.  
3.5.3 Study IV 
Group differences were presented using descriptive statistics. Cox proportional hazards 
regression analysis was used to estimate hazard ratios (HR) for survival across the ACS 
administration-to-birth interval categories. Based on available knowledge on optimal timing 
for ACS administration, the category 48 h to 7 days was considered as reference category, i.e. 
HR = 1.00. HRs for neonatal and infant survival in relation to ACS administration-to-birth 
intervals were evaluated in a multiple Cox proportional hazards regression model adjusting 
for possible confounders or covariates. Cumulative neonatal and infant survival adjusted for 
covariates was also determined using Kaplan–Meier survival analyses. The odds for 
surviving without major neonatal morbidity were analysed using a multiple logistic 
regression model. A p-value <0.05 was considered statistically significant. The large sample 
size allowed for adjusted analyses of survival in relation to timing of ACS-administration and 
several potential confounders. The observational study design means we have to be careful 
interpreting a causative relationship and we cannot exclude that other confounding factors 
than those included herein were unevenly distributed between categories and may have 
affected our results.  
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3.6 ETHICAL CONSIDERATIONS 
The studies included in the thesis were approved by the Ethical Review Board in Stockholm 
(study I-III, 2007/898-31) and in Lund (study IV, 42-2004).  
3.6.1 Register studies  
In study I and IV, data from different registers were used and study subjects did not have to 
do any extra tests. The ethical considerations are related to the registration itself. Individuals 
could be uncomfortable knowing that there is information about them available in registers. 
All patient material in the presented studies has been handled with a high level of 
confidentiality. For the EXPRESS-registry, the parents provided oral informed consent for 
data acquisition. 
3.6.2 Follow-up studies 
Study II and III were follow-up studies and participation required written informed consent. 
The ethical considerations are related to the potential discomfort of being identified as an 
individual at risk. One can assume that the majority of the invited individuals exposed to 
ACS in utero were not even aware of the exposure or the possible negative effects from the 
exposure. We made sure to always answer questions and worries from the participants. As a 
rule, we did not give the participants individual feedback on assessment results but 
information was given if asked for.  
In all the studies, results were presented at group level and no individual result could be 
revealed. 
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4 RESULTS 
4.1 REPEAT ACS AND BIRTH SIZE (STUDY I) 
4.1.1 Description of study population 
The group characteristics of the study population in study I are presented in table 4.  
Table 4. Group characteristics of study I 
 2 courses n 28 
3 courses 
n 26 
≥4 courses 
n 40 p 
MATERNAL DATA 
Age, years, mean (SD) 31.5 (±4.9) 31.6 (±6.0) 30.8 (±4.6) ns 
Height, cm, mean (SD) 166.8 (±6.3) 167.2 (±6.2) 168.4 (±5.0) ns 
Primipara, n (%) 16 (57) 19 (73) 26 (65) ns 
Smoker, n (%) 10 (36) 2 (8) 4 (10) 0.01 
Prepregnancy hyperten-
sion/preeclampsia, n (%) 0 (0) 6 (23) 5 (13) 0.03 
PREGNANCY DATA 
Gestational age, n (%) 
<32 w 
32-36 w 
≥ 37 w 
 
5 (18) 
18 (64) 
5 (18) 
 
8 (31) 
15 (58) 
3 (12) 
 
6 (15) 
29 (73) 
5 (13) 
ns 
GA at start of ACS, w, 
mean (SD) 30.0 (±1.7) 29.2 (±2.2) 27.4 (±1.5) 
<0.001 
Total dose ACS, mg, 
mean (SD) 36 (±3) 48 74 (±15) 
<0.001 
Multiplets, n (%) 11 (39) 13 (50) 16 (40) ns 
INFANT DATA 
Boys, n (%) 15 (54) 18 (69) 26 (65) ns 
Year of birth, n (%) 
1983-1987 
1988-1992 
1993-1996 
 
8 (29) 
12 (43) 
8 (29) 
 
6 (23) 
13 (50) 
7 (27) 
 
4 (10) 
15 (38) 
21 (53) 
ns 
 
4.1.2 Smaller birth size after ACS exposure 
We found that increasing doses of ACS was associated with a significant reduction in 
standard deviation scores for BW, BL and HC (table 5). The mean BW-SDS after two 
courses of ACS was -0.21 which was significantly higher than the mean BW-SDS observed 
after 4 or more ACS courses (-1.01, p = 0.04), (table 5 and figure 14). The mean BL-SDS 
was -0.19 after two courses of ACS and -1.04 after four or more courses (p = 0.07), and the 
mean HC-SDS was 0.25 after two courses of ACS and -0.23 after four or more courses (p = 
0.04) (table 5).  
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In the final multiple regression model adjusting for maternal age, height, parity, smoking, and 
blood pressure disease, multiple pregnancy, gestational age and infant sex we saw that 
exposure to four or more ACS courses was associated with a birth weight of -0.36 SDS 
(corresponding to -151 g for girls and -156 g for boys at term equivalent age) compared to 
those exposed to two or three courses of ACS (p = 0.007, R2 = 0.15). The corresponding 
numbers for birth length was -0.43SDS (= -0.75 cm in girls and -0.81 cm in boys at term 
equivalent age) (p = 0.01, R2 = 0.15) and for head circumference -0.22 SDS (p = 0.04, R2 = 
0.10).  
Table 5. Neonatal anthropometry in relation to number of ACS courses. Data are mean (95% CI) 
 2 courses 
n 28 
3 courses 
n 26 
≥ 4 courses 
n 40 
p 
Birth weight, SDS -0.21 (-0.61, 0.19) -0.47 (-0.96, 0.02) -1.01 (-1.46, 0.56) 0.04 
Birth length, SDS -0.19 (-0.66, 0.28) -0.32 (-0.87, 0.23) -1.04 (-1.60, -0.48) 0.07 
HC, SDS 0.25 (-0.14, 0.64) 0.26 (-0.09, 0.61) -0.23 (-0.52, 0.06) 0.04 
 
 
Figure 14. Standard deviation scores for birth weight in relation to ACS exposure. Data are mean 
(95% CI). 
Unexposed 2 3 ≥4
controls courses of ACS
0.4
0
-0.4
-0.8
-1.2
BW-SDS
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4.1.3 Gestational age at start of ACS and birth size 
We found no association between GA at start of ACS and size at birth. After adjusting for 
GA at birth and sex, there was no correlation between GA at the start of ACS therapy and 
BW-SDS (p = 0.85), BL-SDS (p = 0.26) and HC-SDS (p = 0.076). 
 
4.2 REPEAT ACS AND LATER CARDIOMETABOLIC AND 
NEUROPSYCHOLOGICAL OUTCOME (STUDY II & III) 
4.2.1 Description of study population 
The characteristics of the participants in the follow-up studies are presented in table 6. 
4.2.2 Cardiovascular risk profile in adolescence and young adulthood after 
repeat courses of ACS (study II) 
There were no significant differences between the groups regarding body mass index, systolic 
or diastolic blood pressures, arterial stiffness measured by augmentation index, blood lipids, 
insulin resistance, or morning cortisol levels, either in simple regression or in multivariable 
models (table 7).  
However, subjects with an elevated AI had been exposed to a mean of 4.2 courses of ACS 
compared with a mean of 1.9 courses of ACS in participants with normal AI (p = 0.0048), 
and although not statistically significant (p = 0.06), there were more subjects with elevated AI 
who had been exposed to repeat courses of ACS in fetal life (n = 7) compared with 
unexposed subjects (n =1).  
In addition we found that glucose, insulin, and IR correlated weakly to GA at start of ACS 
(glucose β = -0.06 mmol/L per week longer gestation at start of ACS, r = -0.29, p = 0.007; 
insulin β = -12.9 pmol/L, r = -0.36, p = 0.001; and HOMA-IR β = -0.17 per week longer 
gestation at start of ACS, r = -0.32, p = 0.004). 
In this study, 13% of the participants were overweight and 4% were obese, which is 
consistent with national statistics on overweight and obesity among young adults in Sweden 
(Statistics Sweden, Survey of living conditions, 2010-2011). Furthermore, as expected at 
young adult age, we found limited number of individuals with high BP, elevated blood lipids, 
or IR, indicating that the cohort is representative for Swedish conditions. 
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Table 6. Group characteristics of study II and III. Data are mean ±SD or n (%). 
 Unexposed 
n=42 
1 course of ACS 
n=25 
≥2 courses of ACS 
n=58 
p 
Invited, n 103 48 90  
Parental data 
Maternal age, years 30.9 ±5.3 28.7 ±4.8 32.0 ±5.1 0.03 
Primipara 20 (48) 18 (72) 26 (45) 0.06 
Maternal smoking 7 (17) 3 (13) 7 (12) 0.79 
Parental educationA 
High school or less 
Professional 
Academic 
 
9 (21) 
6 (14) 
27 (64) 
 
10 (40) 
6 (24) 
9 (36) 
 
19 (33) 
6 (10) 
33 (57) 
 
0.16 
Exposure data 
GA at 1st ACS 
course, weeks 
_ 30.6 ±1.3 28.7 ±2.1 <0.001 
Total ACS dose, 
mg 
_ 23.2 ±2.8 55.4 ±20.7 - 
Infant data 
Twin/triplet 9 (21) 5 (20) 29 (50) 0.002 
Male sex 23 (55) 14 (56) 36 (62) 0.74 
Gestational age at 
birth, weeks 
34.7 ±2.9 32.2 ±2.9 33.6 ±2.5 0.002 
Birth weight, g 2 534 ±702 1 909 ±593 2248 ±638 0.001 
Birth weight, SDS -0.2 ±1.1 -0.8 ±1.2 -0.4 ±1.1 0.10 
Major perinatal 
complications B 
5 (11.4) 6 (24.0) 7 (12.1) 0.29 
Characteristics at follow-up 
Age, yrs 18.5 ±2.8 18.0 ±3.4 17.8 ±3.0 0.58 
Menarche, yrs 12.9 ±1.2 12.4 ±4.2 12.4 ±1.0 0.68 
Smoking C 4 (10) 2 (8) 9 (16) 0.12 
Snuff C 4 (10) 3 (12) 1 (2) 0.21 
Oral contraceptives 
among girls 
6 (32) 5 (45) 2 (7) 0.07 
CVD or DM in 1st - 
2nd grade relative 
29 (69) 13 (52) 43 (74) 0.15 
Swedish not first 
language 
5 (11.4) 1 (4.0) 2 (3.4) 0.23 
A The parent with highest education, B Includes at least 1 of the following: mechanical ventilation, 
neonatal seizures, sepsis, bronchopulmonary dysplasia, any degree of retinopathy of prematurity, or 
intraventricular hemorrhage, C On a daily basis  
CVD = cardiovascular disease, DM = diabetes mellitus 
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Table 7. Anthropometry, BP, arterial stiffness, and metabolic outcomes in relation to ACS 
exposure. Data are mean ±SD if not stated otherwise 
 Unexposed 
n=42 
≥2 courses of ACS 
n=58 
p 
Anthropometry 
Weight, kg 66.4 ±11.1 65.4 ±13.8 0.68 
Height, cm 173.8 ±9.1 173.7 ±8.5 0.94 
BMI, kg/m2 
Overweight, n (%) 
Obese , n (%) 
22.0 ±3.3 
7 (17) 
1 (2) 
21.4 ±3.5 
6 (10) 
3 (5) 
0.35 
0.36 
0.47 
Waist, cm 
(>88cm/>102cm,♀/♂) 
82.7 ±10.3 
7 (17) 
81.3 ±9.5 
5 (9) 
0.48 
0.23 
Blood pressure and arterial stiffness 
SBP, mmHg  
>95th percentile, n (%) 
121 ±13 
3 (7) 
120 ±12 
4 (7) 
0.83 
0.96 
DBP, mmHg  
>95th percentile, n (%) 
71 ±9 
1 (2.4) 
70 ±9 
1 (1.7) 
0.62 
0.82 
AoSBP, mmHg 102 ±10 101 ±10 0.60 
AoDBP, mmHg 72 ±8 71 ±9 0.51 
AI, % 
elevated, n (%) 
2.2 ±6.6 
1 (2) 
2.3 ±9.8 
7 (12) 
0.95 
0.06 
Lipid profile 
triglycerides, mmol/L  
elevated, n (%) 
0.8 ±0.4 
1 (2) 
0.9 ±0.7 
4 (7) 
0.62 
0.29 
cholesterol, mmol/L  
elevated, n (%) 
4.1 ±0.7 
3 (7) 
4.1 ±0.8 
4 (7) 
0.81 
0.96 
HDL, mmol/L  1.3 ±0.4 1.3 ±0.4 0.94 
LDL, mmol/L 2.5 ±0.7 2.4 ±0.6 0.55 
LDL/HDL 
elevated, n (%)  
2.2 ±0.9 
0 
2.1 ±0.8 
0 
0.96 
 
ApoA1, g/L 1.5 ±0.2 1.5 ±0.3 0.99 
ApoB, g/L 0.8 ±0.2 0.8 ±0.2 0.83 
ApoB/ApoA1 
elevated, n (%) 
0.54 ±0.15 
1 (2) 
0.53 ±0.14 
0 
0.86 
0.19 
Lipoprotein(a), mg/L 
elevated, n (%) 
270 ±290 
3 (7) 
331 ±437 
5 (9) 
0.71 
0.79 
Glucose/insulin profile 
Glucose, mmol/L 4.9 ±0.4 5.0 ±0.4 0.18 
Insulin, pmol/L 66 ±33 70 ±70 0.90 
HOMA-IR 1.2 (0.6) 1.2 (1.0) 0.84 
Cortisol 
Cortisol, nmol/L 490 ±203 475 ±187 0.79 
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4.2.3 Neuropsychological functioning in adolescence and young adulthood 
after repeat courses of ACS (study III) 
We found that exposure to repeat courses of antenatal corticosteroids was not associated with 
general deficits in higher cognitive functions, self-reported attention, adaptability, or overall 
psychological function. However, among the 21 outcome measurements included to tap 
executive functions, four revealed significant univariate group differences between 
unexposed subjects and subjects exposed to repeat courses of ACS (table 8.) All four were 
found in the domain of attention and speed. After adjusting for covariates, only two measures 
remained significant, the other two reached near statistical significance. In addition, the two 
group differences were not dose-dependent; the subgroup exposed to two courses had the 
lowest means and the group exposed to three courses had the highest. 
There were no significant associations between repeat ACS exposure and verbal or nonverbal 
ability. Memory and learning were also unrelated to repeat exposure to antenatal 
corticosteroids. 
There were no differences between groups in scores from self-report inventories on 
psychological health. Self-reported ADHD-symptoms were not increased in the exposed 
groups; neither was there any differences regarding life satisfaction obtained by self-rated 
quality of life inventory. 
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Table 8. Selected neuropsychological outcomes after repeat courses of ACS. Data are mean ±SD 
  Unexposed 
(n=44) 
 Repeat ACS 
(n=58) 
 p  Adjusted mean 
difference  
[95% CI] 
Adjus
ted p 
General Cognitive 
Ability 
           
 Block Design 47.7 ±9.8  46.4 ±11.5  0.54     
 Vocabulary, 
normed z-score 
-0.19 ±1.2  -0.20 ±0.99  0.96     
Memory and 
Learning 
           
 RAVL 54.0 ±6.6  54.9 ±7.0  0.51     
 RAVL - Retention 12.5 ±1.9  12.8 ±1.8  0.43     
Working Memory            
 Spatial Working 
Memory, Between 
errors 
10.9 ±8.8  12.6 ±11.1  0.41     
 Digit Span 
Backward 
7.0 ±1.9  6.4 ±2.0  0.11     
Attention and Speed            
 Rapid Visual 
Processing 
0.90 ±0.05  0.88 ±0.05  0.02  -0.02 [-0.04 to 0.00] 0.05 
 Trail Making Test, 
TMT-A, Digits 
28.7 ±11.1  32.6 ±12.5  0.11     
 Digit Span 
Forward 
9.7 ±1.9  8.7 ±1.8  0.007  -0.91 [-1.65 to -0.17] 0.02 
 Symbol Search 40.3 ±6.5  35.8 ±7.8  0.003  -3.88 [-6.76 to -1.01] 0.009 
 Coding 74.2 ±13.5  67.1 ±16.1  0.02  -5.63 [-11.73 to 0.48] 0.07 
Cognitive Flexibility 
and Inhibition 
           
 Trail Making Test, 
TMT-B 
64.6 ±23.5  72.2 ±21.4  0.10     
 Verbal Fluency 2, 
Category 
42.6 ±9.0  42.7 ±9.2  0.95     
 Design fluency 2, 
Total 
31.1 ±6.7  29.1 ±6.7  0.15     
 Intra/extradimensio
nal shift, Adjusted 
errors 
21.6 ±18.3  26.6 ±19.4  0.19     
 Signal stop time, 
Signal stop reaction 
time 
178 ±33  190 ±47  0.16     
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4.3 ACS IN EXTREMELY PRETERM GESTATIONS (STUDY IV) 
4.3.1 Description of study population 
Characteristics of the study group are presented in table 9. 
Table 9. Perinatal characteristics of live births according to the administration-to-birth interval 
of ACS. Data are numbers (%). 
 Administration-to-birth interval of ACS 
 no ACS 
n=85 
<24h 
n=149 
24-47h 
n=66 
48h-7d 
n=171 
>7d 
n=103 
ACS but 
unknown 
timing 
n=102 
p 
Maternal 
characteristics 
       
Smoker 9 (10.6) 15 (10.1) 5 (7.6) 27 (15.8) 12 (11.7) 16 (15.7) 0.74 
Hypertensive 
disease* 3 (3.5) 12 (8.1) 9 (13.6) 29 (17.0) 12 (11.7) 21 (20.6) <0.01 
Obstetric 
characteristics 
       
Born at level 
III hospital 26 (30.6) 107(71.8) 62 (93.9) 157(91.8) 98 (95.2) 85 (83.3) <0.001 
Tocolytic 
treatment 23 (27.1) 119(79.9) 42 (63.6) 111(64.9) 61 (59.2) 55 (53.9) <0.001 
PPROM 12 (14.1) 11 (7.4) 11 (16.7) 31 (18.1) 20 (19.4) 18 (17.7) <0.001 
Placenta previa 4 (4.7) 2 (1.3) 3 (4.6) 6 (3.5) 7 (6.8) 5 (4.9) 0.33 
Placenta 
abruption 13 (15.3) 9 (6.0) 5 (7.6) 14 (8.2) 13 (12.6) 13 (12.8) 0.15 
Infant 
characteristics 
       
Gestational age 
at birth, w 
       
22 29 (34.1) 11 (7.4) 1 (1.5) 3 (1.8) 0 5 (4.9)  
23 14 (16.5) 28 (18.8) 14 (21.2) 26 (15.2) 4 (3.9) 13 (12.8)  
24 7 (8.2) 32 (21.5) 13 (19.7) 38 (22.2) 25 (24.3) 22 (21.6) <0.001 
25 22 (25.9) 40 (26.9) 22 (33.3) 52 (30.4) 29 (28.2) 32 (31.4)  
26 13 (15.3) 38 (25.5) 16 (24.2) 52 (30.4) 45 (43.7) 30 (29.4)  
SGA 6 (7.1) 12 (8.1) 13 (20.0) 41 (24.0) 20 (19.4) 22 (21.6) <0.001 
Male gender 44 (51.8) 78 (52.4) 32 (48.5) 92 (53.8) 58 (56.3) 67 (65.7) 0.23 
Multiplets 15 (17.6) 41 (27.5) 18 (27.3) 30 (17.5) 23 (22.3) 26 (25.5) 0.18 
Surfactant <2 h 
after birth  27 (31.8) 94 (63.1) 32 (48.5) 84 (49.1) 57 (55.3) 60 (58.8) 0.001 
*essential hypertension and/or preeclampsia and/or eclampsia. 
PPROM = preterm prelabor rupture of membranes; SGA = small for gestational age (birth weight 
>2SD below the mean of national standard). 
 
 
4.3.2 Neonatal and infant survival in relation to ACS and administration-to-
birth intervals 
The outcomes evaluated in this study were neonatal (alive at 28 days) and infant (alive at 365 
days) survival and infant survival without major morbidity (survival without any of the 
following; IVH ≥3, cystic PVL, NEC, ROP ≥3 or severe BPD). We found clear associations 
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between timing of ACS and survival in extremely preterm infants (table 10 and figure 15). In 
the final model, adjusting for maternal smoking, maternal blood pressure disease, placenta 
previa, placental abruption, PPROM, regionalization of care, gestational age, SGA, infant 
gender and surfactant therapy within 2 h after birth, we found that the lowest HRs for 
neonatal and infant survival were found among infants unexposed to ACS. Extremely 
preterm infants born <24 h after ACS as well as those born more than 7 days after ACS 
administration also had lower HRs for survival than the reference category (infants born 48 h 
to 7 days after ACS administration). Survival in infants born at 24–47 h did not differ from 
that in infants born 48 h to 7 days after ACS administration (table 10). 
In the fully adjusted model, there were no statistically significant difference between the 
exposed groups regarding infant survival without major morbidity, however odds ratios in 
infants unexposed to ACS were significantly lower as expected (table 10). 
 
Table 10. Association between the administration-to-birth interval of ACS and survival among 
live-born infants 
 
 Administration-to-birth interval of ACS 
 no ACS 
n=85 
<24h 
n=149 
24-47h 
n=66 
48h-7d 
n=171 
>7d 
n=103 
ACS but 
unknown 
timing 
n=102 
 Adjusted hazard ratio (95% confidence interval) 
Neonatal 
survival 28 
days 
0.22 
(0.12-0.38) 
0.44 
(0.26-0.74) 
2.08 
(0.80-5.47) reference 
0.54 
(0.29-1.03) 
0.46 
(0.26-0.83) 
Infant 
survival 
365 days 
0.26 
(0.15-0.43) 
0.53 
(0.33-0.87) 
1.60 
(0.73-3.50) reference 
0.56 
(0.32-0.97) 
0.53 
(0.31-0.90) 
 Adjusted odds ratio (95% confidence interval) 
Infant 
survival 
without major 
morbidity 
0.33 
(0.16-0.69) 
0.65 
(0.39-1.08) 
0.67 
(0.35-1.29) reference 
0.59 
(0.35-1.02) 
0.75 
(0.43-1.30) 
 
In summary, we found that shorter or longer administration-to-birth intervals than 24 h to 7 
days were associated with an approximately doubled risk for neonatal and infant mortality. 
The lowest survival was found in infants unexposed for ACS – their adjusted infant mortality 
risk was five times higher than in infants in the reference group exposed to ACS 48 h to 7 
days before birth. 
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Figure 15. Adjusted survival curve for extremely preterm infants related to ACS treatment and 
administration-to-birth intervals. 
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5 DISCUSSION 
5.1 REPEAT ACS AND BIRTH SIZE 
A vast amount of studies on animals have previously shown a correlation between ACS 
exposure and restricted fetal growth. For example, birth weights of preterm lambs decreased 
with 11–15% after one course, with 19% after two and with 25–27% after 3 weekly courses 
of betamethasone.104,133 In rabbits, Pratt et al showed a significant reduction in birth weight 
with increasing doses of antenatal betamethasone. Late treatment resulted in a greater decline 
in birth weight than did the same doses given at an earlier gestational age.134 Studies in 
humans however have showed more conflicting results where some have found a correlation 
between ACS and size at birth whereas others have not (chapter 1.2.5.1). The reasons for the 
different results in animal and human studies could be explained by differences between 
species in sensitivity to the glucocorticoid receptors, and differences in dosing and type of 
glucocorticoids (dexamethasone instead of betamethasone) and stages of pregnancy among 
studies. The conflicting results in human studies could possibly be explained by limitations in 
power or the use of actual birth weight as an outcome instead of BW-SDS – corrected for sex 
and gestational age – which is a more appropriate outcome measure. In order to more 
accurately assess the effects of ACS on fetal growth, repeated assessments of fetal body size 
in utero would be a better way forward. 
Results from our study are in line with results from animal studies, showing that increasing 
courses of ACS were associated with a significant reduction in SDS for BW, BL and HC, 
even after adjusting for possible confounders. There was a clear trend towards a linear dose–
response relationship between increasing number of ACS courses and smaller size at birth, 
whereas GA at the start of ACS was not associated with birth size.  
The strengths of this study include the use of predefined criteria for exposure and outcome 
data, eliminating problems with recall or other forms of recording bias. The cohort consisted 
of almost 100 exposed infants, which allowed for analyses with sufficient power to discover 
clinically important effects. Confounders of fetal growth and birth size were controlled for. 
By investigating anthropometry in a group of unexposed, healthy, term infants born at the 
same hospital and during the same time period as the infants in the exposed study group, we 
can conclude that the anthropometry of our subjects are representative for Swedish 
conditions. Finally, the majority of infants were born moderately preterm without major 
pregnancy complications, refining the possibility to disclose effects of ACS exposure without 
significant interference from severe maternal or perinatal morbidity. The limitations include 
the fact that although an association between increasing number of ACS courses and 
reduction in birth size was found, we still have to be cautious about interpretations of a 
causative relationship. This is an observational study, and although several other risk factors 
were controlled for in the analyses, confounding cannot be excluded.  
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5.2 REPEAT ACS AND LATER METABOLIC/CARDIOVASCULAR FUNCTION 
Excess glucocorticoid exposure in fetal life has, as mentioned in previous chapters, been 
suggested to be a major mechanism for adverse early programming. Previous studies in 
animals have shown that both single and repeat courses of ACS can have lasting adverse 
effects on neuroendocrine function, blood pressure and glucose homeostasis.135 The 
mechanisms behind this could be that excessive exposure to glucocorticoids in utero have 
been shown to negatively alter nephron development, renin-angiotensin-aldosterone system, 
baroreceptor function, elastin synthesis, and vascular function in animal studies,106,136,137 as 
well as altered neurohormonal regulation, altered insulin signalling and reduced β -cell 
function.64,138,139 The impact of excessive fetal glucocorticoid exposure on later 
cardiovascular and metabolic function in humans are however not as obvious. A few human 
studies have shown a possible correlation between ACS and later adverse cardiovascular risk 
profile. For example, Doyle et al showed that ACS to pregnant women was associated with 
higher blood pressure in their 14 year old offspring68, and Dalziel et al showed higher insulin 
levels 30 years after ACS exposure.65 Most of the follow-up studies in humans after ACS 
exposure have, as mentioned in previous chapters, not been able to show such a correlation. 
Accordingly, ACS administered to human fetuses appears to be less harmful than when 
administered to experimental animals. Besides species differences, exposure to 
corticosteroids earlier in pregnancy in animal studies, as well as use of higher doses and of 
dexamethasone instead of betamethasone, may be part of the explanation to why 
experimental and clinical research have come to different conclusions. It is also possible that 
postnatal influences might be more influential in humans, making the effects of antenatal 
steroids more difficult to detect.  
Results from our study are in line with results from RCTs reported in preschool children and 
extends this knowledge to adolescence and young adulthood, showing that also at older age, 
repeat courses of ACS are not associated with changes in body weight/BMI, BP, blood lipids, 
glucose, insulin, or cortisol.  
Arterial stiffness, as measured by mean AI, did not differ between groups, however, the 
number of subjects with an elevated AI was higher (n = 7) in the group exposed to repeat 
ACS courses compared with the unexposed group (n = 1). In a fairly recent observational 
study of slightly older adults exposed to ACS and born at an earlier GA, increased aortic arch 
stiffness was associated with use of ACS.69 Aortic narrowing and alterations in aortic 
elasticity are in line with recent experimental research showing that lambs born preterm had 
thicker aortic walls and a smaller aortic lumen, and that elastin deposition was markedly 
increased in the aorta of lambs born preterm.106 In that experimental study, it was not possible 
to determine the role of ACS. To do so, aortic structure and function should receive specific 
attention in forthcoming follow-up studies after randomized controlled trials testing efficacy 
and safety of repeat ACS courses. In addition, differences in pulse wave reflection and AI 
may reflect structural and functional differences in other parts of the vascular tree distal to the 
large arteries.  
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Our study showed no difference in glucose, insulin, or IR between unexposed and exposed 
subjects. However, glucose, insulin, and IR were inversely associated with GA at start of 
ACS. This finding supports previous suggestions that sensitivity to ACS, as regards glucose 
metabolism later in life, is dependent on GA.69 Given that earlier ACS exposure could 
contribute to higher glucose and insulin levels 20 years later, this finding, although not 
clinically relevant in our study group, may have special implications for the discussion 
around safety of repeated ACS courses in older individuals than those studied herein and in 
pregnancies with extremely short duration. 
The major strengths of this study include the cohort of individuals of both sexes exposed to 
varying numbers of weekly courses of ACS, and the long-term and detailed follow-up into 
adolescence or adulthood. Other strengths include the use of predefined criteria for exposure, 
eliminating problems with recall bias. All registry data have been prospectively collected and 
the assessment at follow-up was blinded to perinatal exposures. Finally, the majority of the 
infants in the study groups were born moderately preterm without major pregnancy or 
neonatal complications, refining the possibility to disclose effects of ACS exposure without 
significant interference from maternal and perinatal morbidity or postnatal steroid exposure. 
The small size of our cohort and the observational study design are limitations. Furthermore, 
we cannot exclude selection bias in study participation. There was an overrepresentation of 
individuals with low birth weight SDS among nonparticipants, and such bias may influence 
the lack of association between exposure and outcome. In addition, our findings do not apply 
to extremely preterm infants exposed to repeat courses of ACS and born before 28 weeks of 
gestation. 
5.3 REPEAT ACS AND LATER NEUROPSYCHOLOGICAL FUNCTION 
There is a large collection of evidence from animal studies suggesting that excessive GC 
exposure in utero affects the developing brain in many ways resulting in subtle or drastic 
changes in subsequent function. As described in chapter 1.2.4.3, ACS reduces brain mass and 
delays myelination in animals. In addition, it is known that the hippocampus highly expresses 
glucocorticoid and mineralocorticoid receptors and is particularly vulnerable to 
glucocorticoid manipulations140 and changes in hippocampal structure and function have in 
numerous studies been shown to alter cognitive ability, behaviour and the risk of 
psychological disorders later in life.141,142 In human studies, excessive exposure to synthetic 
GC has reassuringly not been found to cause as much adverse effects on neuropsychological 
function as feared. In a western Australian cohort, repeat courses of ACS was not associated 
with changes in general cognitive ability or in internalizing behaviour, however, they found 
an increased risk of aggressive-destructive behaviour, hyperactivity and distractibility at 3 
and 6 years of age.86 In addition, Spinillo et al found that repeat courses of ACS could have 
adverse effects on neurodevelopmental outcome in 2-year-old children, but that was true 
primarily for those exposed to dexamethasone rather than betamethasone.143 The RCTs on 
repeat courses of ACS have, as mentioned before, showed no obvious correlation between 
ACS exposure and neuropsychological function in preschool/early school years (table 1).  
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The results from our study are in line with those from the RCTs indicating that repeat courses 
of ACS are not associated with deficits in higher cognitive functions or psychological health. 
However, mean scores obtained on 2 tests, Symbol Search and Digit Span Forward, were 
significantly lower for the repeat group compared with the unexposed group. Both measures 
fall within the executive domain of attention and speed, which reduces the likelihood that 
they are mere statistical artefacts attributable to multiple comparisons. Although deficits in 
test scores cannot be equated with behaviour problems in everyday life, the modest group 
differences in test scores observed in our cohort may be functionally related to the behaviour 
problems found in preschool children in other studies mentioned above. Previous studies in 
nonhuman primates investigating the long-term effects of fetal glucocorticoid overexposure 
on prefrontal cortex gene expression have found significant effects of this treatment on the 
expression of glucocorticoid receptors and that these effects were more pronounced in 
neonates than in adults.144 It is tempting to speculate that the modest effects observed in our 
cohort of adolescents and young adults are remnants of deficits that were more clearly 
expressed in the younger preschool children in previous studies but have been compensated 
for in later development. In our dose-response analysis, we did not find any relationship 
between the number of corticosteroid courses and outcome. These findings are reassuring, 
given the dose-dependent reduction in neonatal anthropometrics previously reported to occur 
in this cohort. The lack of a dose-response effect could though be a result of sampling bias, 
given the small number of participants in each subgroup.  
The strengths and limitations of this study are similar to those of study II (see chapter 5.2). 
Worth noticing is that this study does not address the issue of long term cognitive outcome in 
subjects exposed to repeat courses of antenatal corticosteroids and born before 28 weeks of 
gestation, it is feasible that exposure earlier in fetal life could have a different outcome. 
5.4 ACS IN EXTREMELY PRETERM GESTATIONS 
It is important to note that the evidence supporting ACS at <26 weeks' gestation is based 
mainly on laboratory studies and non-RCTs. However, given the results from many 
observational studies145 suggesting a strong positive effect of ACS also in extremely preterm 
gestations, it would seem non-ethical to conduct RCTs on this subject. 
Animal and in vitro lung tissue studies have shown that ACS might have beneficial effect on 
the lungs even at very early gestations.146,147 This is supported by the findings in our study 
showing that the lowest survival was found in infants unexposed to ACS – their adjusted 
infant mortality risk was five times higher than in infants in the reference group exposed to 
ACS 48 h to 7 days before birth.  
Animal and in vitro studies have also shown the greatest benefits from ACS on surfactant 
production when delivery occurs between 24 h and 7 days after a complete course of 
ACS.148,149 However, human studies are contradictory. Some studies have found a decline in 
the effectiveness of ACS over time126,150,151, whereas others failed to do so.152-154 In addition 
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there is new evidence supporting a much faster effect of ACS on the fetus than previously 
known. Results from the EPICE (Effective Perinatal Intensive Care in Europe)-cohort 
showed that infant mortality decreased significantly when ACS was administered only a few 
hours before birth.129 Previous knowledge has suggested that ACS given prior to 24 hours 
before birth had poor effectiveness. In our study we found that shorter or longer 
administration-to-birth intervals than 24 h to 7 days were associated with a doubled risk for 
infant mortality. These results are in line with a recent study where the authors found that 
ACS for preterm birth at 24–34 weeks of gestation had maximum beneficial impact on 
neonatal morbidity and mortality when administered 1– 7 days before birth. In that study, the 
decline in effectiveness of ACS after 7 days was primarily observed among neonates born at 
early gestations (24–28 weeks).126 
The strengths of our study include prospective enrolment of all extremely preterm births in 
Sweden over a 3-year period. The study was one of the largest and the only population-based 
cohort evaluated for effects of ACS, and of timing of ACS, in all live-born infants born at 22–
26 weeks of gestation. The ACS administration-to-birth interval was prospectively collected 
in hours. The outcomes were robust and clinically highly relevant. The sample size allowed 
for adjusted analyses of survival in relation to timing of ACS-administration and several 
potential confounders.  
It is worth noting that we excluded stillborn infants. Among stillborn infants alive at onset of 
labour, a minority (n = 22/66; 30%) had been treated with ACS, meaning that these fetuses 
had been proactively managed. Excluding intrapartum mortality may therefore have 
introduced some bias, overestimating the protective effects of ACS at the time it was 
administered. However, under the premise that the infant was live-born, our risk estimates of 
no or untimely ACS are valid. The EXPRESS-database does not contain specific information 
on reasons for not treating with ACS; however, a recommendation to withhold treatment 
rested mainly on regional guidelines about management of extremely short gestations or 
severe malformations. Among infants born at 22 weeks of gestation, 29/49 (59%) did not 
receive ACS, at 23 weeks of gestation the corresponding proportion was 14/99 (14%), and in 
infants born at 24 weeks of gestation the proportion not receiving ACS was 7/137 (5.1%). 
Accordingly, crude estimates of survival in relation to ACS exposure and administration-to-
birth intervals are likely to be confounded by indication. To resolve this issue, we only 
presented mortality data adjusted for gestational age. Another limitation is the small numbers 
of 22-week fetuses, with only 20 exposed to ACS and five survivors, making generalizability 
of our findings to this group limited. Further, we cannot exclude that other confounding 
factors than those included in the study affected our results. Moreover, our results cannot be 
extrapolated to other drugs or dosing regimens than the ones used in Sweden. Finally, the 
included infants were born a decade ago. Since then, neonatal care has improved even more 
and the evidence for less invasive ventilation strategies has become clearer.155 Still, we think 
our findings are generalizable for the current extremely preterm population as in recent 
national statistics, the proportions of infants born at 22–26 weeks of gestation in Sweden who 
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were intubated at birth and mechanically ventilated were similar to those in EXPRESS. (Data 
from the Swedish Neonatal Quality registry). 
5.5 GENERAL DISCUSSION 
The studies included in this thesis have contributed to the knowledge about antenatal 
corticosteroid treatment. Both about its life-saving effects in extremely preterm infants, and 
its potentially adverse effects in a short and longer term perspective.  
It is very well established that ACS is one of the most important interventions for improving 
outcome after preterm birth and that one single course of ACS is of no harm to the exposed 
child. Therefor, it is utterly important to optimize the administration of ACS, making sure 
that the treatment is given to all eligible mothers with threatening preterm delivery. The 
treatment rate could be improved by a more proactive management also in extremely preterm 
gestations and by considering ACS to women at risk for imminent preterm delivery in the 
next hours.  
Whether or not to repeat the ACS course to women who remain undelivered seven or more 
days after the initial course is still unclear. Summarizing the evidence from previous studies 
and adding the knowledge from the papers included in this thesis, one can conclude that 
despite the emerging body of evidence linking fetal glucocorticoid exposure to permanent 
changes in homeostasis and organ function in experimental studies, there are little evidence 
of harm following exposure to repeat courses of ACS in humans. In view of the additive 
neonatal benefits following repeat ACS it would seem appropriate to consider at least one 
single rescue course of ACS to women who didn´t deliver one week or more after the initial 
course and who again are at risk of preterm delivery.  
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6 CONCLUSIONS  
Repeat antenatal corticosteroids and birth size: 
Ø Repeat courses of antenatal corticosteroids (ACS) are associated with a decline in 
birth size, which may have implications for later development and health. 
Ø The reduction seen in birth size after repeat courses of ACS is dose-dependent. 
Ø Gestational age at start of ACS exposure is not related to reduced size at birth. 
Repeat antenatal corticosteroids and later metabolic/cardiovascular function: 
Ø Repeat courses of ACS are not associated with changes in body weight/body mass 
index, central or peripheral blood pressure, blood lipids, glucose, insulin, or cortisol at 
follow-up 14 to 26 years after birth. 
Ø Long-standing effects on the arterial tree and glucose metabolism, the latter 
dependent on gestational age at ACS exposure, cannot be excluded. 
Repeat antenatal corticosteroids and later neuropsychological function: 
Ø Repeat courses of ACS are not correlated to adverse effects on higher cognitive 
functions and behaviour at follow-up 14 to 26 years after birth. 
Ø Repeats courses of ACS may have an impact on some aspects of executive 
functioning regarding attention and speed.  
Antenatal corticosteroids in extremely preterm gestations: 
Ø Exposure to ACS has a clear positive effect on morbidity and survival also in 
extremely preterm infants. 
Ø The optimal time-interval for administration of ACS is 24 hours to 7 days before 
birth. 
Ø Shorter or longer administration-to-birth intervals than 24 hours to 7 days are 
associated with a markedly increased risk of neonatal and infant mortality. 
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7 FUTURE PERSPECTIVES 
Although much research has been conducted on this subject there are still many unanswered 
questions and evidence gaps to be filled. Future research areas should include testing: 
Ø The lowest effective glucocorticoid dose 
− It is not known if a lower dose of glucocorticoids could be as effective as the 
current dosing regime. If a lower dose of ACS can be shown to be equally 
effective, side effects may be reduced and it could possibly lead to a more 
proactive management of repeating the courses to women undelivered after the 
initial course of ACS. 
Ø The optimal timing of glucocorticoid administration before preterm birth 
− It is not fully clear how fast ACS can exert its effect on the fetus and how long the 
effect lasts. Very recent data challenge the current thinking about optimal timing 
of ACS129 and more research on this area is warranted.  
Ø The effect of ACS in low-resource settings 
− Almost all studies on ACS have been conducted in high-income countries; 
therefore, the results may not be applicable to low-resource settings with high 
rates of infections. A recent cluster-randomised trial in low- and middle-income 
countries surprisingly showed that ACS led to increased neonatal mortality in the 
population.156 More research on this area is crucial. 
Ø The effect of ACS in multiple pregnancies and other high-risk obstetric groups 
− There are insufficient data regarding risks and benefits of ACS on high-risk 
obstetric groups such as multiple pregnancies, premature rupture of membranes 
and hypertension syndromes.12 
Ø The possible adverse effects of repeat courses of ACS into adulthood  
− Although results from follow-up studies into childhood after repeat courses of 
ACS are reassuring there is a need for follow-up into adulthood before we can 
conclude that repeat courses of ACS is a safe treatment. The RCTS on this subject 
will have to wait decades until the included children have become adults; hence, 
observational studies are also warranted. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Att födas för tidigt är vanligt i Sverige och resten av världen. Tack vare stora förbättringar i 
vården av den gravida kvinnan och det nyfödda barnet kan numera barn som är födda så 
tidigt som graviditetsvecka 22-23 överleva. Majoriteten av de för tidigt födda barnen 
överlever utan några bestående men medan en andel av framförallt de extremt för tidigt födda 
barnen drabbas av olika funktionsnedsättningar. Exempel på sådana funktionsnedsättningar 
kan vara försämrad syn, nedsatt lungfunktion, neurologisk påverkan eller nedsatt kognitiv 
funktion. Dessutom löper de för tidigt födda barnen en ökad risk för folksjukdomar såsom 
diabetes och hjärt-kärlsjukdomar senare i livet.  
En stor förklaring till att fler överlever tidig födsel är att man på 70-talet införde behandling 
med kortison till gravida kvinnor som riskerar att föda sitt barn för tidigt. Behandlingen kallas 
för antenatal kortisonbehandling och fungerar bl a så att kortisonet får fostrets lungor att 
mogna snabbare. När barnet sedan föds är det bättre rustat att andas själv och får mer sällan 
och mindre allvarlig lungsjukdom än barn vars mammor inte fått kortison. Det är även visat 
att behandlingen minskar risken för hjärnblödning, infektioner och allvarliga tarmåkommor 
hos det nyfödda barnet. Pga de positiva effekterna är antenatal kortisonbehandling en väldigt 
vanlig behandling över hela världen. Dock finns det en oro för att behandlingen eventuellt 
kan ge biverkningar på barnet. Denna oro har uppstått pga att forskningsstudier på djur har 
visat att det finns starka kopplingar mellan antenatal kortisonbehandling och bieffekter på bl a 
fostertillväxt och hjärnans utveckling samt ökad risk för hjärt-kärlsjukdomar och 
neuropsykologiska funktionsnedsättningar senare i livet. Huruvida denna koppling även finns 
hos människor är inte lika tydligt och det behövs mer forskning inom området för att ta reda 
på om så är fallet. 
Huvudsyftet med denna avhandling var dels att undersöka om det finns något samband 
mellan antenatal kortisonbehandling och olika biverkningar på barnet på kort sikt samt senare 
i livet. Vi har därför undersökt en grupp om ca 100 individer födda på Danderyds sjukhus 
under åren 1983-1996 och som under fosterlivet exponerats för varierande doser av kortison. 
I studie I undersökte vi om behandlingen påverkar tillväxten av fostret och vi fann att det 
finns ett sådant samband. Barn som hade utsatts för höga doser kortison i fosterlivet var både 
lättare, kortare och hade ett något mindre huvudomfång vid födseln än normalt. Man vet 
sedan tidigare att en hämmad fostertillväxt kan leda till hälsoproblem senare i livet varför 
detta är en potentiellt allvarlig biverkan. I studie II och III följde vi upp dessa barn i tidig 
vuxen ålder (14-26 år) för att undersöka om kortisonbehandlingen var kopplad till ökad risk 
för antingen hjärt-kärlsjukdom (studie II) eller neuropsykologiska funktionsnedsättningar 
(studie III). Vi fann inga tydliga samband mellan kortisonbehandling i fosterlivet och senare 
ohälsa i vår studiegrupp vilket är en viktig iakttagelse för att kunna fortsätta rekommendera 
behandlingen utan oro för framtida biverkningar. Det behövs dock fler studier på fler 
individer och i äldre åldrar för att kunna befästa denna iakttagelse. 
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I studie IV undersökte vi en grupp barn som fötts extremt för tidigt (före graviditetsvecka 27) 
i Sverige. Vi ville undersöka om antenatal kortisonbehandling var lika effektiv även bland 
dessa väldigt tidigt födda barn vilket inte har studerats i någon större utsträckning tidigare. Ett 
annat syfte med studien var att undersöka om det är viktigt att ge kortisonbehandlingen vid ett 
visst tidsintervall före förväntad födsel. Vi fann att bland de ca 700 barnen i vår undersökta 
grupp hade antenatal kortisonbehandling en tydlig och stark positiv effekt på barnens 
överlevnad. Våra resultat visade även att för störst skyddseffekt så ska behandlingen ges 1-7 
dygn före beräknad förlossning.  
Denna avhandling har bidragit till ökad kunskap angående antenatal kortisonbehandling. 
Sammanfattningsvis kan vi från resultatet av våra studier konstatera att: 
• Antenatal kortisonbehandling påverkar fostrets tillväxt negativt men effekten 
tycks vara övergående då inga skillnader i längd och vikt sågs vid 
långtidsuppföljning. 
• Till skillnad från djurstudier verkar inte antenatal kortisonbehandling hos 
människa leda till ökad risk för metabol ohälsa eller neuropsykologiska 
funktionsnedsättningar i ung vuxen ålder. 
• Antenatal kortisonbehandling har en livräddande effekt även på extremt för tidigt 
födda barn. 
• Det är viktigt att ge kortisonbehandlingen vid rätt tidpunkt för att uppnå optimal 
effekt. 
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